We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tilray Brands, Inc. (TLRY) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Read MoreHide Full Article
Tilray Brands, Inc. (TLRY - Free Report) ended the recent trading session at $1.88, demonstrating a -9.18% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 3.7%. On the other hand, the Dow registered a loss of 1.93%, and the technology-centric Nasdaq decreased by 5.28%.
Shares of the company have depreciated by 29.35% over the course of the past month, underperforming the Medical sector's gain of 1.11%, and the S&P 500's loss of 6.62%.
Market participants will be closely following the financial results of Tilray Brands, Inc. in its upcoming release. The company is expected to report EPS of -$0.15, up 63.41% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $269.2 million, up 23.76% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.52 per share and a revenue of $1.11 billion, signifying shifts of +52.29% and +21.43%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Tilray Brands, Inc. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Tilray Brands, Inc. is currently a Zacks Rank #4 (Sell).
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 149, placing it within the bottom 40% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Image: Bigstock
Tilray Brands, Inc. (TLRY) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Tilray Brands, Inc. (TLRY - Free Report) ended the recent trading session at $1.88, demonstrating a -9.18% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 3.7%. On the other hand, the Dow registered a loss of 1.93%, and the technology-centric Nasdaq decreased by 5.28%.
Shares of the company have depreciated by 29.35% over the course of the past month, underperforming the Medical sector's gain of 1.11%, and the S&P 500's loss of 6.62%.
Market participants will be closely following the financial results of Tilray Brands, Inc. in its upcoming release. The company is expected to report EPS of -$0.15, up 63.41% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $269.2 million, up 23.76% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.52 per share and a revenue of $1.11 billion, signifying shifts of +52.29% and +21.43%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Tilray Brands, Inc. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Tilray Brands, Inc. is currently a Zacks Rank #4 (Sell).
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 149, placing it within the bottom 40% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.